BioMotiv
BioMotiv is a Cleveland-based therapeutic accelerator, founded in 2012, that builds and funds a portfolio of novel medicines sourced from academic and institutional partners, serving as a development intermediary between early-stage science and pharmaceutical partners.
- Company typePrivate
- Founded2012
- HeadquartersCleveland, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
BioMotiv firmographics
Firmographics- Name
- BioMotiv
- Website
- https://biomotiv.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioMotiv is a Cleveland-based therapeutic accelerator, founded in 2012, that builds and funds a portfolio of novel medicines sourced from academic and institutional partners, serving as a development intermediary between early-stage science and pharmaceutical partners.
- Ownership category
- akta.pro rank
BioMotiv industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Translational Medicine & Biomarkers (HLAIALAF)
- akta.pro secondary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where BioMotiv is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Markets served
BioMotiv business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
BioMotiv product offering
Product offeringCore offering
BioMotiv is a therapeutic accelerator that identifies, in-licenses, de-risks, and advances a portfolio of novel therapeutic candidates from academic and early-stage sources toward clinical development. The company funds and manages drug development programs across multiple therapeutic areas, leveraging partnerships with biopharmaceutical companies, academic medical centers, and patient foundations.
Differentiator
Problem solved
Functional benefit
Products and services
- Therapeutic Accelerator Program
Companies that use BioMotiv
Customer profileIdeal customer profiles2 records
BioMotiv technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BioMotiv competitors and assessment
Company assessmentDirect peers
- Cydan Development: Accelerator focused on identifying and de-risking therapeutic candidates for rare diseases, spinning out NewCos around validated assets — same accelerator/venture-creation playbook as BioMotiv.
- Atlas Venture: Venture firm that builds biotech companies from inception around early-stage therapeutic programs, often via in-house translation. Comparable to BioMotiv as a competing model for early drug-discovery capital.
- Bridge Medicines: Drug-development accelerator created by Memorial Sloan Kettering, Rockefeller, and Weill Cornell that in-licenses early-stage discoveries and advances them toward IND — directly comparable to BioMotiv's therapeutic accelerator model.
- Accelerator Life Science Partners: Early-stage biotech investment and operating platform that incubates and builds therapeutic companies, directly competing for translational-stage assets and partnerships.
Broad incumbents
- Flagship Pioneering: Large biotech creation engine that conceives, launches, and operates multiple therapeutic platform companies — a more established, broader incumbent operating in the same therapeutic-acceleration space as BioMotiv.
- Deerfield Management: Healthcare-focused investment firm with dedicated therapeutic-company creation capabilities and academic-partnership programs; competes with BioMotiv for translational-stage deals and academic licenses.
Others
- Indiana University School of Medicine / AMPATH Health (illustrative academic partner): Comparable model of academic-medical-center-anchored translational drug-development partnerships that serve as feedstock sources for accelerators like BioMotiv.
- National Institutes of Health (NCATS): Federal translational-science entity that funds and operates therapeutic development programs; serves as an ecosystem participant influencing deal flow, funding, and competition for translational-stage assets comparable to BioMotiv's pipeline.
Market position
Customer concentration
BioMotiv social profiles
Digital presenceBioMotiv financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioMotiv leadership team
Management profileNumber of profiles
Profiles4 records
BioMotiv funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioMotiv M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioMotiv
What does BioMotiv do?
BioMotiv is a therapeutic accelerator that identifies, in-licenses, de-risks, and advances a portfolio of novel therapeutic candidates from academic and early-stage sources toward clinical development. The company funds and manages drug development programs across multiple therapeutic areas, leveraging partnerships with biopharmaceutical companies, academic medical centers, and patient foundations.
When was BioMotiv founded?
BioMotiv was founded in 2012. It employs 11 to 50 people.
Where is BioMotiv based?
BioMotiv is headquartered in Cleveland, United States, in the North America region.
Who are BioMotiv's main competitors?
Direct peers on record are Cydan Development, Atlas Venture, Bridge Medicines and Accelerator Life Science Partners. Broad incumbents are Flagship Pioneering and Deerfield Management. Others are Indiana University School of Medicine / AMPATH Health (illustrative academic partner) and National Institutes of Health (NCATS).
Does BioMotiv have an API?
No public API is recorded for BioMotiv.
What industry is BioMotiv in?
BioMotiv's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2834.